2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

4:30PM-6:00PM: Abstract Number: 2058

Ectonucleotidase-Mediated Protection of Lupus Mice from Exaggerated Immune Responses and Arterial Vasculopathy

Systemic Lupus Erythematosus – Animal Models

4:30PM-6:00PM: Abstract Number: 2044

Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders

4:30PM-6:00PM: Abstract Number: 2054

Effect of Temporary Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

Rheumatoid Arthritis – Clinical Aspects III: Prevention of Comorbidity

4:30PM-6:00PM: Abstract Number: 2084

Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study

ARHP IV: Clinical Practice, Patient Care and Health Services

4:30PM-6:00PM: Abstract Number: 2048

Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study

Reproductive Issues in Rheumatic Disorders

4:30PM-6:00PM: Abstract Number: 2071

Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2043

Feasibility and Accuracy of Translating a Patient Safety Quality Measure into an Automated e-Measure

Quality Measures and Quality of Care I

4:30PM-6:00PM: Abstract Number: 2072

Fli1-Haploinsufficient Dermal Fibroblasts Promote Skin-Localized Transdifferentiation of Th2- and Th17-like Regulatory T Cells

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2032

Genome-Wide Association Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci

Genetics, Genomics and Proteomics I

4:30PM-6:00PM: Abstract Number: 2078

Global Ethnic and Geographic Differences in the Clinical Features of ANCA-Associated Vasculitis

Vasculitis II: Population Studies

4:30PM-6:00PM: Abstract Number: 2074

Herpes Zoster and the Risk of Incident Giant Cell Arteritis

Vasculitis II: Population Studies

4:30PM-6:00PM: Abstract Number: 2082

Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)

ARHP IV: Clinical Practice, Patient Care and Health Services

4:30PM-6:00PM: Abstract Number: 2063

Identification of Microrna Predictive of Outcome in Lupus Nephritis

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

4:30PM-6:00PM: Abstract Number: 2077

Impact of Diabetes, Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Statin Use on Presentation and Outcomes in Patients with Giant Cell Arteritis

Vasculitis II: Population Studies

4:30PM-6:00PM: Abstract Number: 2047

Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].